Brenntag showcases innovations in beauty and personal care at Indonesia Cosmetic Ingredients 2025

Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs

Revvity launches AI-powered software to transform preclinical imaging analysis

The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities

AbbVie submits application to FDA for Tavapadon for treatment of Parkinson's disease

If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option

Enhertu improved in invasive disease-free survival in early breast cancer in DB-05

Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

The Lancet Regional Health publishes pivotal phase 3 clinical study on Miqnaf

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1

The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population

Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer

Importantly, the combination of giredestrant and everolimus was well tolerated

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent

FDA approves Merck's Keytruda injection for cancer therapy

Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute